Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00411086
Status:
COMPLETED
Last Update Posted:
2017-12-05
First Post:
2006-12-11
Brief Title:
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lymphoma |
Keywords:
| Name | View |
|---|---|
| Rituxan | View |
| contiguous stage II grade 1 follicular lymphoma | View |
| contiguous stage II grade 2 follicular lymphoma | View |
| contiguous stage II grade 3 follicular lymphoma | View |
| noncontiguous stage II grade 1 follicular lymphoma | View |
| noncontiguous stage II grade 2 follicular lymphoma | View |
| noncontiguous stage II grade 3 follicular lymphoma | View |
| stage I grade 1 follicular lymphoma | View |
| stage I grade 2 follicular lymphoma | View |
| stage I grade 3 follicular lymphoma | View |
| stage III grade 1 follicular lymphoma | View |
| stage III grade 2 follicular lymphoma | View |
| stage III grade 3 follicular lymphoma | View |
| stage IV grade 1 follicular lymphoma | View |
| stage IV grade 2 follicular lymphoma | View |
| stage IV grade 3 follicular lymphoma | View |
| Granulocyte-Macrophage Colony Stimulating Factor | View |
| GM-CSF | View |
| Rituximab | View |